EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Blockade of the lncRNA-PART1-PHB2 axis confers resistance to PARP inhibitor and promotes cellular senescence in ovarian cancer

Huan Wu, Chenggong Sun, Wenyu Cao, Qiuli Teng, Xinyue Ma, Helgi B Schiöth, Ruifen Dong, Qing Zhang, Beihua Kong

Cancer Letters · 2024-10 · 602 · 217192

DOI: 10.1016/j.canlet.2024.217192 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2024-10. Verfasst von Huan Wu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Ji'nan, Shandong, 250012, PR China; Gynecology Oncology Key Laboratory…. Hauptthemen laut MEDLINE: Cellular Senescence, Drug Resistance, Neoplasm, Ovarian Neoplasms, Poly(ADP-ribose) Polymerase Inhibitors. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PARPi is currently the most important breakthrough in the treatment of ovarian cancer in decades, and it has been integrated into the initial maintenance therapy for ovarian cancer. However, the mechanism leading to PARPi resistance remains unelucidated. Our study aims to screen novel targets to better predict and reverse resistance to PARPi and explore the potential mechanism. Here, we conducted a comparative analysis of differentially expressed genes between platinum-sensitive and platinum-resistant groups within the TCGA ovarian cancer cohort. The analysis indicated that lncRNA PART1 was significantly highly expressed in platinum-sensitive patients compared to platinum-resistant individuals in TCGA-OV cohort and further validated in the GEO dataset and Qilu hospital cohort. Moreover, the upregulation of PART1 was positively correlated with a favorable prognosis in ovarian cancer. Furthermore, in vitro and in vivo experiments showed that inhibition of PART1 conferred resistance to both cisplatin and PARP inhibitor and promoted cellular senescence. Senescent cells are more resistant to chemotherapeutics. RNA antisense purification and RNA immunoprecipitation assays revealed an interaction between PART1 and PHB2, a crucial mitophagy receptor. Knockdown of PART1 could promote the degradation of PHB2, impairing mitophagy and leading to cellular senescence. Rescue assays indicated that overexpression of PHB2 remarkably diminished the resistance to PARPi and cellular senescence caused by PART1 knockdown. PDX models were utilized to further confirm the findings. Altogether, our study demonstrated that lncRNA PART1 has the potential to serve as a novel promising target to reverse resistance to PARPi and improve prognosis in ovarian cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cellular SenescenceDrug Resistance, NeoplasmOvarian NeoplasmsPoly(ADP-ribose) Polymerase InhibitorsRNA, Long NoncodingAnimalsFemaleHumansMiceCell Line, TumorCell ProliferationCisplatinGene Expression Regulation, NeoplasticMice, NudePrognosisRepressor ProteinsXenograft Model Antitumor AssaysProhibitins

Stichwörter der Autor:innen

Cellular senescenceLncRNA PART1Ovarian cancerPARP inhibitorPHB2

Substanzen

CisplatinPoly(ADP-ribose) Polymerase InhibitorsRepressor ProteinsRNA, Long NoncodingPHB2 protein, humanProhibitins

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Ji'nan, Shandong, 250012, PR China; Gynecology Oncology Key Laboratory, Qilu Hospital of Shandong University, Ji'nan, Shandong, 250012, PR C…
  • Department of Surgical Sciences, Functional Pharmacology and Neuroscience, Uppsala University, Uppsala, Sweden.

Zitieren

APA

Wu, H., Sun, C., Cao, W., Teng, Q., Ma, X., Schiöth, H. B., Dong, R., Zhang, Q., & Kong, B. (2024). Blockade of the lncRNA-PART1-PHB2 axis confers resistance to PARP inhibitor and promotes cellular senescence in ovarian cancer. Cancer Letters, 602, 217192. https://doi.org/10.1016/j.canlet.2024.217192

Vancouver

Wu H, Sun C, Cao W, Teng Q, Ma X, Schiöth HB, et al. Blockade of the lncRNA-PART1-PHB2 axis confers resistance to PARP inhibitor and promotes cellular senescence in ovarian cancer. Cancer Letters. 2024;602:217192. doi:10.1016/j.canlet.2024.217192

BibTeX
@article{Wu2024,
  author = {Wu, Huan and Sun, Chenggong and Cao, Wenyu and Teng, Qiuli and Ma, Xinyue and Schiöth, Helgi B and Dong, Ruifen and Zhang, Qing and Kong, Beihua},
  title = {Blockade of the lncRNA-PART1-PHB2 axis confers resistance to PARP inhibitor and promotes cellular senescence in ovarian cancer},
  journal = {Cancer Letters},
  year = {2024},
  volume = {602},
  pages = {217192},
  doi = {10.1016/j.canlet.2024.217192}
}
Kostenlos starten →